Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen Maintenance in DLBCL
NCT06355401Phase 3Not yet recruiting
- Sponsor
- Sohag University
- Start
- Apr 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of tamoxifen in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Sohag University. Primary endpoints: Disease Free Survival and Overall Survival. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
tamoxifen
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06355401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06355401.